China Biologic Products Holdings Files Prospectus Following $4.76 Billion Privatization Backed by Leading Global Investors

On April 20, 2021, China Biologic Products Holdings, Inc. (NASDAQ: CBPO), a leading integrated blood products and biopharmaceutical enterprise in China (hereinafter referred to as “China Biologics”), announced that the privatization acquisition of China Biologics had been officially completed. The company also announced that its shares would cease trading effective immediately and that it had initiated the delisting process from the NASDAQ Global Select Market.

On November 19, 2020, Taibang Biological Group announced that it had reached an acquisition agreement with the buyer consortium. On March 1, 2021, the transaction was approved at a special general meeting of shareholders of Taibang Biological Group.

Under the agreement, the transaction price is $120 per share, valuing the company at approximately $4.76 billion. The buyer consortium already holds approximately 68.84% of Taibang Biological’s shares. In addition to management members, the consortium includes several prominent institutions such as Centurium Capital, CITIC Capital, Hillhouse Capital, Temasek, Bailin Capital, and Ping An Venture Capital.

Taibang Biological Group was established in 2002 and is a leading integrated blood products and biopharmaceutical enterprise in China, with core businesses encompassing the research and development, production, and sales of blood products and biological products. As a leader in the blood products industry, Taibang Biological Group operates the largest blood products production base in Asia with internationally advanced technology; boasts an industry-leading R&D team and state-of-the-art blood products research laboratories; and maintains a comprehensive product portfolio covering three major categories—albumin, immunoglobulins, and coagulation factors—with more than 20 product specifications.

In addition, the Group’s non-blood-product business segment operates multiple product lines, including artificial dura mater, artificial spinal dura mater, artificial nerve sheath conduits, and tendon membranes, as well as a full range of neurosurgical products under the German brand Zeppelin. Its products cover the medical markets in all provinces, municipalities, and autonomous regions across mainland China.

In the future, Taibang Bio will further enhance its R&D capabilities and operational excellence across plasma collection, research and development, manufacturing, and sales. With the goal of becoming a world-leading biopharmaceutical and biotechnology company, Taibang Bio is committed to creating value for patients and advancing human health.